Emcure Pharma shares advance 10% as Kotak Equities sees 28% upside in stock

Expecting a further pickup in Emcure Pharmaceuticals’ organic growth in 2HFY25, domestic brokerage firm Kotak Institutional Equities upgraded the stock’s rating to ‘buy’ from an ‘add’ earlier, with a target price of Rs 1,680.

This signals an upside potential of 28% from Monday’s stock closing price.

“After a decent 1HFY25 print, we expect a further pick-up in Emcure’s organic growth in 2HFY25, with upbeat prospects across India, Canada and ROW. Compared to 6% yoy in 1HFY25, we estimate 9% yoy overall organic growth in 2HFY25E,” said Kotak in its report.

Led by healthy organic growth, an in-licencing deal with Sanofi, consolidation of Mantra and with most of the legal challenges behind, Emcure is expected to report a 13% overall sales CAGR over FY2024-27E. On a low base, improved productivity post the 20%+ field force addition since FY2022 is expected and higher utilisation of the new facilities is likely to drive robust 18%/29% EBITDA/EPS CAGRs, over FY2024-27E.

On the international front, it is expected that Emcure’s organic business in Canada will report a strong 16% YoY growth in 2HFY25. Moreover, aided by the Mantra deal (consolidated from Nov 2023), the domestic brokerage firm forecasts a robust 19% Canada sales CAGR, over FY2024-27E.

Also, a pick-up in ARV sales is expected, with strong traction for Tenecteplase to drive an 11% ROW sales CAGR, over FY2024-27E.Emcure is one of the few major Indian pharma players with no meaningful direct US generics exposure, thereby lending greater earnings stability.Also read: Vodafone Idea shares zoom 18% on in-principle Cabinet nod for bank guarantee waiver

Led by its R&D prowess, Emcure has built a complex portfolio (40% of sales), comprising chiral molecules, iron compounds and biologics. It is a leading player in gynaecology and has also scaled up brands across multiple therapies, such as cardiac, VMN, anti-infectives and antivirals, leading to one of the highest prescription coverages (71%) among specialists in the IPM.

A renewed focus is likely to drive robust 13%/18%/29% overall sales/EBITDA/EPS CAGRs, over FY2024-27E.

However, further repercussions due to the drug price-fixing cases in the US/Canada, further litigations such as the now-resolved one with HDT Biocorp and the inability to consistently outperform IPM growth are the key risks stated by Kotak Equities.

The shares of Emcure Pharma were trading 5.6% higher at Rs 1,384.75 on the BSE around 12 noon on Tuesday.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Todays Chronic is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – todayschronic.com. The content will be deleted within 24 hours.

Leave a Comment